Fig. 2
From: Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
Decrease in CD39 expression and extracellular ATP accumulation in human CD8+ T cells in presence of hCD39-specific ASO. Human anti-CD3, anti-CD28, and IL-2 activated CD8+ T cells were treated with 5 μM of the hCD39 specific ASO A04040H or the control oligo 1 for a total treatment time of six days. hCD39 protein expression was analyzed by flow cytometry. (a) Residual hCD39 expression of oligonucleotide-treated cells relative to mock-treated cells (set to 1). (b) After six days of ASO treatment, 2 μM of ATP were added to cells or cell-free medium. ATP concentration in cell supernatants was determined after 30 min of incubation with ATP and is presented relative to cell-free medium (set to 1). Data is shown as mean of triplicates +/− SD. Asterisks indicate significant differences compared to control oligo treatment